“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Progressing towards the development of
Producing quality medicines in areas of
Producing high quality affordable
and accessible biologics
Mumbai, August 11, 2017: The Board of Directors, Lupin Limited announced today the unanimous appointment of Mrs. Manju Deshbandhu Gupta as Chairman. Mrs. Gupta has been a member of the board for over 40 years and has been an important pillar of strength for the company.
The board felt that this is a deserving recognition for one of the co-founders and first investor of the company and is an important step in ensuring continuity. This non-executive role will be for a period of two years.
Commenting on the appointment, Mrs. Gupta said “I am honored with the confidence that the board has placed in me and I look forward to working with the board to take Lupin to greater heights. I am also very pleased that Dr. Kamal Sharma will continue to guide the management team for another year. I look upon my role as helping to take Dr. Deshbandhu Gupta’s legacy forward and transitioning over the next two years to Vinita and Nilesh.”
About Lupin Limited
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
Lupin is the 7th and 6th largest generics pharmaceutical company by market capitalization (June 30th, 2017, Bloomberg) and revenues (March 31st, 2017, Bloomberg) respectively. The Company is the 4th largest pharmaceutical player in the US by prescriptions (Quintiles IMS MAT March 2017); 2nd largest Indian pharmaceutical company by global revenues (March 31st, 2017, Bloomberg); 6th largest generic pharmaceutical player in Japan and 6th largest company in Indian Pharmaceutical Market (Quintiles IMS MAT June 2017). For the financial year ended 31st March, 2017, Lupin’s Consolidated sales and Net profit stood at Rs. 171,198 million (USD 2.55 billion) and Rs. 25,575 million (USD 381 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinlimited
CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.
For further information or queries please contact –
VP – Corporate Communications
Head – Investor Relations and M&A